A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
A phase 3 trial of Cadonilimab in gastric & gastro-oesophageal junction cancer, run by Akeso, now recruiting.
Overview
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma is a phase 3 interventional study registered as NCT07023315 by Akeso, with 760 participants planned, started 2025-08-14 and due to reach its primary completion in 2029-07. Interventions recorded: Cadonilimab, SOX chemotherapy and Placebo.
Similar pages
not linked directly; found by shared links- TrialA Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
Shares Cadonilimab, Akeso and the tag pipeline.
- TrialDV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Shares Cadonilimab, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Shares Cadonilimab, Akeso and the tag pipeline.
- TrialA Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
Shares Akeso and the tag pipeline.
- TrialA Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Shares Akeso and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Shares Akeso and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Shares Akeso and the tag pipeline.
- TrialStudy to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.